Cargando…

The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions

BACKGROUND: To assess the biochemical recurrence (BCR)-free rate in patients who underwent prostate low-dose-rate brachytherapy (LDR-brachytherapy), using two different definitions (Phoenix definition and PSA ≥ 0.2 ng/mL). METHODS: Two hundreds and three patients who were clinically diagnosed with l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Nobumichi, Asakawa, Isao, Katayama, Emiko, Hirayama, Akihide, Hasegawa, Masatoshi, Konishi, Noboru, Fujimoto, Kiyohide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029825/ https://www.ncbi.nlm.nih.gov/pubmed/24885896 http://dx.doi.org/10.1186/1748-717X-9-107

Ejemplares similares

Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy
por: Tanaka, Nobumichi, et al.
Publicado: (2013)

Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2012)

Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
por: Tanaka, Nobumichi, et al.
Publicado: (2014)

Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2017)

Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case report
por: Hori, Shunta, et al.
Publicado: (2014)

Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2019)

Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent Retropubic Radical Prostatectomy
por: Tanaka, Nobumichi, et al.
Publicado: (2012)

Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2019)

The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions
por: Miyake, Makito, et al.
Publicado: (2019)

Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2018)

Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases
por: Miyake, Makito, et al.
Publicado: (2017)

Localized prostate cancer with pelvic arteriovenous malformation treated with low‐dose‐rate brachytherapy after transcatheter embolization: Two case reports
por: Owari, Takuya, et al.
Publicado: (2019)

Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study
por: Miyake, Makito, et al.
Publicado: (2014)

Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute
por: Miyake, Makito, et al.
Publicado: (2017)

Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009
por: Tanaka, Nobumichi, et al.
Publicado: (2013)

A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study
por: Miyake, Makito, et al.
Publicado: (2020)

The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram
por: Tanaka, Nobumichi, et al.
Publicado: (2015)

Follow-up study of unilateral renal function after nephrectomy assessed by glomerular filtration rate per functional renal volume
por: Hosokawa, Yukinari, et al.
Publicado: (2014)

Quality of life worsened the most severely in patients immediately after intensity-modulated radiotherapy for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2018)

The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer
por: Tanaka, Nobumichi
Publicado: (2023)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Direct Comparison of Two Different Definitions with Biochemical Recurrence after Low-Dose-Rate Brachytherapy for Prostate Cancer
por: Takeuchi, Shinichi, et al.
Publicado: (2023)

Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient’s age and prostate volume
por: Hori, Shunta, et al.
Publicado: (2019)

Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model
por: Inoue, Takeshi, et al.
Publicado: (2013)

Review by urological pathologists improves the accuracy of Gleason grading by general pathologists
por: Nakai, Yasushi, et al.
Publicado: (2015)

Editorial Comment on Ischemic proctitis after low‐dose‐rate brachytherapy using hydrogel spacer for prostate cancer
por: Tanaka, Nobumichi
Publicado: (2022)

Definitive three-dimensional high-dose-rate brachytherapy for inoperable endometrial cancer
por: Draghini, Lorena, et al.
Publicado: (2017)

Improvement of the surgical curability of locally confined prostate cancer including non-organ-confined high-risk disease through retropubic radical prostatectomy with intentional wide resection
por: Okajima, Eijiro, et al.
Publicado: (2012)

Overactive bladder induces transient hypertension
por: Torimoto, Kazumasa, et al.
Publicado: (2018)

Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2020)

Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012
por: Tanaka, Nobumichi, et al.
Publicado: (2017)

A new nomogram of urinary flow rate and volume based on multiple measurements per healthy adult Japanese men using a portable uroflowmeter (P-Flowdiary®)
por: Shinohara, Masatake, et al.
Publicado: (2022)

Response to ‘Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer’
por: Slevin, Finbar, et al.
Publicado: (2020)

An examination of the sexual functions of patients who underwent a gynecologic cancer operation and received brachytherapy
por: Guner, Ozlem, et al.
Publicado: (2018)

Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid
por: Nakai, Yasushi, et al.
Publicado: (2014)

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy
por: Tomioka, Atsushi, et al.
Publicado: (2015)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Atypical small acinar proliferation and two or more cores of high-grade intraepithelial neoplasia on a previous prostate biopsy are significant predictors of cancer during a transperineal template-guided saturation biopsy aimed at sampling one core for each 1 mL of prostate volume
por: Nakai, Yasushi, et al.
Publicado: (2017)

Efficacy of FDG-PET for defining gross tumor volume of head and neck cancer
por: Kajitani, Chikae, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sd8qboo7f9rkj10cllo1j8ermn